---
layout: default
title: Irbesartan
description: "Irbesartan çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 4 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 93
evidence_level: L4
indication_count: 4
---

# Irbesartan

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>4</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Irbesartanï¼šå¾ é«˜è¡€å£“ åˆ° æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Irbesartan å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Irbesartanï¼ˆè‰¾æ¯”æ²™å¦ï¼‰æ˜¯ä¸€ç¨®è¡€ç®¡æ”¶ç¸®ç´  II å—é«”æ‹®æŠ—åŠ‘ï¼ˆARBï¼‰ï¼Œç”¨æ–¼æ²»ç™‚é«˜è¡€å£“å’Œç³–å°¿ç—…è…ç—…è®Šã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š (malignant hypertensive renal disease)** å’Œ**è‚ºé«˜å£“ (pulmonary hypertension)** æœ‰æ½›åœ¨é—œè¯ï¼Œç›®å‰ç„¡ç›´æ¥è‡¨åºŠè©¦é©—è­‰æ“šï¼Œä½†æ©Ÿè½‰ä¸Šå…·åˆç†æ€§ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç¬¬äºŒå‹ç³–å°¿ç—…æ‚£è€…çš„é«˜è¡€å£“åŠç³–å°¿ç—…æ€§è…ç—…è®Š |
| é æ¸¬æ–°é©æ‡‰ç—‡ | malignant hypertensive renal diseaseã€malignant renovascular hypertensionã€pulmonary hypertension with unclear multifactorial mechanismã€pulmonary hypertension owing to lung disease and/or hypoxia |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.31% (æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Š) |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 30+ å¼µ |
| å»ºè­°æ±ºç­– | Consider |





## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant hypertensive renal disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Irbesartan é€éé¸æ“‡æ€§é˜»æ–·è¡€ç®¡æ”¶ç¸®ç´  II èˆ‡ AT1 å—é«”çš„çµåˆï¼Œç”¢ç”Ÿè¡€ç®¡æ“´å¼µå’Œé™å£“æ•ˆæœã€‚å…¶åŸé©æ‡‰ç—‡å·²åŒ…å«ã€Œç³–å°¿ç—…æ€§è…ç—…è®Šã€ï¼Œé¡¯ç¤ºå…¶å°è…è‡Ÿçš„ä¿è­·ä½œç”¨ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p>ç›®å‰ç„¡é‡å°æ­¤ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. malignant renovascular hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pulmonary hypertension with unclear multifactorial mechanism</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pulmonary hypertension owing to lung disease and/or hypoxia</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33862277/" target="_blank">33862277</a></td><td>2021</td><td>Article</td><td>Ageing research reviews</td><td>Hypoxia and brain aging: Neurodegeneration or neuroprotection?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37328448/" target="_blank">37328448</a></td><td>2023</td><td>Article</td><td>Advanced science (Weinheim, Ba</td><td>N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39841808/" target="_blank">39841808</a></td><td>2025</td><td>Article</td><td>Science translational medicine</td><td>Hypoxia as a medicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28972206/" target="_blank">28972206</a></td><td>2017</td><td>Article</td><td>Nature reviews. Immunology</td><td>Regulation of immunity and inflammation by hypoxia in immunological niches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34618295/" target="_blank">34618295</a></td><td>2022</td><td>Article</td><td>Metabolic brain disease</td><td>Cognitive impairment caused by hypoxia: from clinical evidences to molecular mec...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31706510/" target="_blank">31706510</a></td><td>2019</td><td>Article</td><td>Trends in cancer</td><td>DUBs, Hypoxia, and Cancer.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21328446/" target="_blank">21328446</a></td><td>2011</td><td>Article</td><td>Journal of cellular biochemist</td><td>Hypoxia-mediated biological control.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40347693/" target="_blank">40347693</a></td><td>2025</td><td>Article</td><td>Redox biology</td><td>Hypoxia in multiple sclerosis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34535359/" target="_blank">34535359</a></td><td>2021</td><td>Article</td><td>Clinical oncology (Royal Colle</td><td>Therapeutic Modification of Hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11172576/" target="_blank">11172576</a></td><td>2000</td><td>Article</td><td>Respiratory care clinics of No</td><td>Mechanisms of hypoxemia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24557798/" target="_blank">24557798</a></td><td>2014</td><td>Article</td><td>Journal of applied physiology </td><td>Translation in progress: hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/4585366/" target="_blank">4585366</a></td><td>1973</td><td>Article</td><td>Revista medica de Chile</td><td>[Cerebral hypoxia].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36100192/" target="_blank">36100192</a></td><td>2022</td><td>Article</td><td>Journal of controlled release </td><td>Research progress on tumor hypoxia-associative nanomedicine.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/2164797/" target="_blank">2164797</a></td><td>1990</td><td>Article</td><td>Annales francaises d&#x27;anesthesi</td><td>[Postanoxia encephalopathies].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37915135/" target="_blank">37915135</a></td><td>2023</td><td>Article</td><td>BMB reports</td><td>Regulation of CMGC kinases by hypoxia.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30423905/" target="_blank">30423905</a></td><td>2018</td><td>Article</td><td>International journal of molec</td><td>Hypoxic Microenvironment and Metastatic Bone Disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/8817697/" target="_blank">8817697</a></td><td>1996</td><td>Article</td><td>Progress in neurobiology</td><td>Hypoxia and brain development.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18345017/" target="_blank">18345017</a></td><td>2008</td><td>Article</td><td>Cell death and differentiation</td><td>Hypoxia-inducible factor: roles in development, physiology, and disease.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27146279/" target="_blank">27146279</a></td><td>2017</td><td>Article</td><td>Cephalalgia : an international</td><td>Hypoxic mechanisms in primary headaches.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28493839/" target="_blank">28493839</a></td><td>2017</td><td>Article</td><td>Oncotarget</td><td>Hypoxia inducible factors in hepatocellular carcinoma.</td></tr>
</tbody>
</table>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026409è™Ÿ | è‰¾å¦¥æç©©è†œè¡£éŒ 300æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç¬¬äºŒå‹ç³–å°¿ç—…æ‚£è€…çš„é«˜è¡€å£“åŠç³–å°¿ç—…æ€§è…ç—…è®Š |
| è¡›éƒ¨è—¥è£½å­—ç¬¬058169è™Ÿ | é™å£“ä½³è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç³–å°¿ç—…æ€§è…ç—…è®Š |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028450è™Ÿ | å„æ¯”å¡è†œè¡£éŒ 150æ¯«å…‹ | è†œè¡£éŒ  | æœ¬æ…‹æ€§é«˜è¡€å£“ã€ç³–å°¿ç—…æ€§è…ç—…è®Š |

## å®‰å…¨æ€§è€ƒé‡

**è—¥ç‰©äº¤äº’ä½œç”¨ï¼ˆä¸­åº¦ï¼‰ï¼š**
- Potassium supplementsï¼šå¯èƒ½å¢åŠ é«˜è¡€é‰€é¢¨éšª
- NSAIDsï¼šå¯èƒ½æ¸›å°‘é™å£“æ•ˆæœå’Œå¢åŠ è…æå‚·é¢¨éšª
- Lithiumï¼šå¯èƒ½å¢åŠ é‹°æ¯’æ€§
- ACE inhibitorsï¼šé›™é‡ RAAS é˜»æ–·å¢åŠ ä¸è‰¯åæ‡‰é¢¨éšª

**ç¦å¿Œç—‡ï¼š**
- æ‡·å­•
- é›™å´è…å‹•è„ˆç‹¹çª„
- åš´é‡è‚åŠŸèƒ½æå®³


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**å¿ƒè‡Ÿè¡°ç«­** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Hyperkalemia** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**Renal Artery Obstruction** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- é€šå¸¸ç„¡éœ€èª¿æ•´åŠ‘é‡ã€‚

**ç³–å°¿ç—…** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚

**Angioedema** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**ä½è¡€å£“** ğŸŸ¢ Minor
- å¯èƒ½éœ€è¦é™ä½åŠ‘é‡ã€‚é¢¨éšªåŒ…æ‹¬ï¼šä½è¡€å£“ã€‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**é…’ç²¾** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚
- å»ºè­°ï¼šå»ºè­°é¿å…ä½µç”¨ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚

**é«˜é‰€é£Ÿç‰©** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”¢ç”Ÿå”åŒä½œç”¨ã€‚å¯èƒ½æŠ‘åˆ¶è—¥ç‰©ä½œç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€é‰€ã€‚
- å»ºè­°ï¼šéœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚


## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šConsider**

**ç†ç”±ï¼š**
Irbesartan çš„ ARB æ©Ÿè½‰å’Œå·²çŸ¥çš„è…è‡Ÿä¿è­·ä½œç”¨ï¼Œä½¿å…¶å°é«˜è¡€å£“æ€§è…ç—…è®Šçš„æ²»ç™‚å…·æœ‰è—¥ç†å­¸åˆç†æ€§ã€‚ç„¶è€Œï¼Œã€Œæƒ¡æ€§ã€é«˜è¡€å£“æ˜¯ä¸€ç¨®éœ€è¦ç·Šæ€¥è™•ç½®çš„æ€¥ç—‡ï¼Œå£æœ ARB æ›´é©åˆä½œç‚ºæ€¥æ€§æœŸå¾Œçš„ç¶­æŒæ²»ç™‚ã€‚é æ¸¬é©æ‡‰ç—‡å¯è¦–ç‚ºåŸé©æ‡‰ç—‡çš„åš´é‡ç¨‹åº¦å»¶ä¼¸ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å›é¡§æ€§ç ”ç©¶åˆ†æ ARB åœ¨æƒ¡æ€§é«˜è¡€å£“è…ç—…è®Šç¶­æŒæœŸçš„ç™‚æ•ˆ
- è©•ä¼°èˆ‡å…¶ä»–é™å£“è—¥çš„æ¯”è¼ƒæ•ˆç›Š
- æ˜ç¢ºæ­¤é©æ‡‰ç—‡æ˜¯å¦ç‚ºåŸé©æ‡‰ç—‡çš„è‡¨åºŠå»¶ä¼¸

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Griseofulvin]({{ "/drugs/griseofulvin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Pitavastatin]({{ "/drugs/pitavastatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Alirocumab]({{ "/drugs/alirocumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ipilimumab]({{ "/drugs/ipilimumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Irbesartanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/irbesartan/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_irbesartan,
  title = {Irbesartanè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/irbesartan/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
